StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to Underweight
April 26, 2016 7:28 AM
Piper Jaffray downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Underweight with a price target of $6.00 (from $15.00).Analyst Edward ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
FDA
Next Articles
Sarepta Therapeutics (SRPT) Continues Grind Higher from Morning Lows
April 26, 2016 12:45 PM
Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next Year
April 26, 2016 7:23 AM
Sarepta Therapeutic (SRPT) PT Cut to $5 at RBC Capital
April 26, 2016 7:14 AM
Sarepta Therapeutics (SRPT) Resumes Trading; Shares down 53%
April 26, 2016 7:11 AM
Sarepta Therapeutics (SRPT) to resume trading at 7:10AM ET
April 26, 2016 7:07 AM
Sarepta Therapeutic (SRPT) PT Cut to $7 at Jefferies Following Negative AdCom
April 26, 2016 6:49 AM
Oppenheimer Downgrades Sarepta Therapeutic (SRPT) to Perform
April 26, 2016 6:40 AM
Sarepta Therapeutics (SRPT) Issues Commentary on Adverse FDA Panel Vote for Eeplirsen in DMD
April 26, 2016 5:58 AM
Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy
April 25, 2016 10:58 PM
FDA Panel 6 YES, 7 NO That Eteplirsen Shows Clinical Benefit (SRPT)
April 25, 2016 6:12 PM
